@article{Huang2022, author = {Hongyun Huang and Ziad M. Al Zoubi and Gustavo Moviglia and Hari Shanker Sharma and Anna Sarnowska and Paul R. Sanberg and Lin Chen and Qun Xue and Dario Siniscalco and Shiqing Feng and Hooshang Saberi and Xiaoling Guo and Mengzhou Xue and Milan R. Dimitrijevic and Russell J. Andrews and Gengsheng Mao and Robert Chunhua Zhao and Fabin Han}, title = {Clinical cell therapy guidelines for neurorestoration (IANR/CANR 2022)☆}, year = {2022}, journal = {Journal of Neurorestoratology}, volume = {10}, number = {3}, pages = {100015}, keywords = {Cell therapy, Neurorestoration, Neurorestoratology, Clinical application guideline}, url = {https://www.sciopen.com/article/10.1016/j.jnrt.2022.100015}, doi = {10.1016/j.jnrt.2022.100015}, abstract = {Cell therapy has been shown to be a crucial clinical therapeutic option for central nervous system diseases or damage. Promoting standardization of clinical cell therapy procedures is essential for professional associations devoted to cell therapy. The International Association of Neurorestoratology (IANR) and the Chinese Association of Neurorestoratology (CANR; Preparatory) collaborated to release Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017) in 2018. Due to recent advances and achievements in clinical cell therapy worldwide in recent years, IANR and CANR have renewed and updated the guidelines. Except for the requirements of equipment, personnel, and ethics, these revised guidelines include cell type nomenclature, cell quality control, cell types in clinical application, minimal suggested cellular doses, patient-informed consent, indications and contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, the policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility. IANR/CANR recommends that all clinical practitioners follow these cellular therapy guidelines. These guidelines provide references of better cell types, doses, routes, and therapeutic timing windows in different diseases.} }